MikeTrendsTrends right now
AI: reposAPI

search

LEQSELVI

Trends

  1. 1
    Two-Year Data for Alopecia Drug LEQSELVI Shows Sustained Efficacy▼New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026✉newsWorldUS Politics6 h ago

    Sun Pharmaceutical announced two-year clinical data for LEQSELVI (deuruxolitinib) in severe alopecia areata, presented at the EADV Congress 2026. The results showed sustained efficacy and a consistent safety profile in patients over the extended treatment period. The findings reinforce the drug's long-term value for people with severe hair loss, though discussion so far appears limited to the announcement itself.